SCHEMBL17834580

SCHEMBL17834580

CC[C@H]1CC[C@H](c2ccc(-c3cnc(-c4ccc(C[C@H](NC(=O)c5ccc(C(C)(C)C)s5)C(=O)NCC(=O)O)cc4)nc3)cc2)CC1

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ KLKB1 P03952 2/20 0.33
▸ CTSB P07858 1/20 0.33
▸ CTSS P25774 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ PRSS1 P07477 5/20 0.33
▸ F10 P00742 2/20 0.33
▸ EGLN1 Q9GZT9 1/20 0.33
▸ KIFC1 Q9BW19 3/20 0.32
▸ PLG P00747 3/20 0.32
▸ PRSS2 P07478 3/20 0.32
▸ PRSS3 P35030 3/20 0.32
▸ PRCP P42785 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834578 0.93 L3MBTL1 (0.37) DGAT1L3MBTL1PRSS1KIFC1PLG
SCHEMBL17825448 0.91 KIFC1 (0.38) DGAT1KIFC1
SCHEMBL17834920 0.91 KIFC1 (0.38) DGAT1KIFC1
SCHEMBL17825447 0.91 KIFC1 (0.38) DGAT1KIFC1
SCHEMBL17825449 0.91 KIFC1 (0.38) DGAT1KIFC1
SCHEMBL17968971 0.90 MME (0.36) DGAT1KLKB1EGLN1KIFC1
SCHEMBL17834510 0.90 MME (0.36) DGAT1KLKB1EGLN1KIFC1
SCHEMBL17834602 0.90 MME (0.36) DGAT1KLKB1EGLN1KIFC1
SCHEMBL17968983 0.90 MME (0.36) DGAT1KLKB1EGLN1KIFC1
SCHEMBL17834549 0.90 MME (0.36) DGAT1KLKB1EGLN1KIFC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R DGAT1 2899/4885L3MBTL1 771/4885KLKB1 2855/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R DGAT1 2899/4885L3MBTL1 771/4885KLKB1 2855/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR DGAT1 2729/4885L3MBTL1 579/4885KLKB1 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback